Clinical trials: mFOLFOX6
Colorectal Neoplasms, Neoplasm Metastasis
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study.
- Trial name
- AFFIRM (NCT00851084)
- Testing
- aflibercept, oxaliplatin, 5-FU
- Where
- 37 sites in Australia, Germany and 5 more
- Volunteers
- 268 people
- Sponsor
- Sanofi
Colorectal Cancer
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread…
- Trial name
- NCT07775287
- Testing
- Petosemtamab, Cetuximab, Bevacizumab
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- Genmab
Metastatic Colorectal Cancer
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
The study is an double blind, randomized, multicenter phase 3 trial. The efficacy analyses are based on 570 Chinese patients with RAS wt mCRC treated with mFOLFOX-6 ± cetuximab.
- Trial name
- NCT03426371
- Testing
- KL-140
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
Compare the objective remission rate of A140 and Erbitux combined with mfolfox6 regimen in the first-line treatment of Ras wild-type metastatic colorectal cancer for 12 weeks
- Trial name
- NCT04835142
- Testing
- Double blind control period A140, Open single period A140
- Where
- China
- Volunteers
- 688 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Trial name
- NCT07673887
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 8 sites in United States, China and 2 more
- Volunteers
- 570 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
This randomized phase II trial studies how well combination chemotherapy and bevacizumab with or without CBP/beta-catenin antagonist PRI-724 (PRI-724) works in treating patients with newly diagnosed colorectal cancer that has…
- Conditions
- Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- PRIMIER (NCT02413853)
- Testing
- CBP/beta-catenin Antagonist PRI-724, Bevacizumab, Leucovorin Calcium
- Where
- United States
- Sponsor
- University of Southern California
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma Cancer
Early Access Program for Zolbetuximab
This program is to provide zolbetuximab to people with stomach cancer or gastroesophageal junction (the junction between stomach and esophagus) cancer who have not yet been treated with chemotherapy, immunotherapy, or…
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma Cancer, Metastatic Gastric Adenocarcinoma Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT06048081
- Testing
- zolbetuximab
- Where
- 140 sites in United States, Brazil and 4 more
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Colorectal Cancer
First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
The association of FOLFOX (5-fluoruracil, folinic acid, and oxaliplatin) and pan is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC patients.
- Trial name
- TRIPLETE (NCT03231722)
- Testing
- Panitumumab, Irinotecan, Oxaliplatin
- Where
- 4 sites in Italy
- Volunteers
- 435 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
The primary objective of the phase 1 portion of this study is to determine the recommended dose of bemarituzumab in combination with 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) to use in the phase 2 portion of…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic, Gastric Cancer
- Trial name
- FIGHT (NCT03343301)
- Testing
- Bemarituzumab, Modified FOLFOX6
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Five Prime Therapeutics, Inc.
Colorectal Cancer
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00321828
- Testing
- bevacizumab, fluorouracil, leucovorin
- Where
- 163 sites in United States
- Volunteers
- 90 people
- Sponsor
- NSABP Foundation Inc
Gastric Cancer
Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer
For gastric patients of Karnofsky scores between 60-80 scores, mFolfox6 is an option for chemotherapy. Neutropenia and oxaliplatin-induced neurotoxicity are the most common adverse effects which even result in discontinue of…
- Trial name
- NCT02024438
- Testing
- monosialotetrahexosylganglioside Sodium
- Where
- 2 sites in China
- Volunteers
- 240 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer, Liver Metastases
Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients
The aim of this study is to explore whether cetuximab in combination with mFOLFOX6 as treatment could improve the resection rate in patients with KRAS wild-type, unresectable liver metastases of mCRC.
- Trial name
- CLIME (NCT01322178)
- Testing
- Cetuximab; mFOLFOX6
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fudan University
Advanced Colorectal Cancer
A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer
This study adopts a randomized, open-label, positive-controlled, multicenter design, aiming to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and bevacizumab versus standard therapy as first-line…
- Trial name
- NCT07676162
- Testing
- SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Hepatocellular Carcinoma
An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC
This study is aimed to establish an organoid-on-chips technological system based on biopsy samples and evaluate its efficacy in predicting the response to mFOLFOX6 infusion in patients with hepatocellular carcinoma (HCC).
- Trial name
- NCT05932836
- Testing
- No interventions.
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Xiangya Hospital of Central South University
Colorectal Cancer
Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
This is a randomized, multicenter study designed to evaluate the progression free survival of the SOL group (S-1, Leucovorin, and Oxaliplatin) compared with the mFOLFOX6 group (5-FU, l-LV and Oxaliplatin) as first-line treatment…
- Trial name
- NCT00721916
- Testing
- SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
- Where
- Japan
- Volunteers
- 107 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Colorectal Cancer
TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
The purpose of this study: To explore the comparative effectiveness of BIBF 1120 in terms of : Progression-free survival (PFS), objective response, overall survival Evaluate and compare safety
- Trial name
- AIO-KRK-0111 (NCT01362361)
- Testing
- mFOLFOX6 + BIBF 1120
- Where
- 12 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Colorectal Cancer
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)
This will be a randomized, open-label, multicenter, Phase II study with primary objectives to assess whether expression of select chemotherapy markers is associated with progression-free survival (PFS) in participants treated…
- Trial name
- MAVERICC (NCT01374425)
- Testing
- 5-Fluorouracil, Bevacizumab, Irinotecan
- Where
- 79 sites in United States, Canada and 5 more
- Volunteers
- 376 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer (CRC)
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
This is a prospective, multicenter, randomized controlled, phase II study. It is expected to enroll 229 patients and aims to evaluate the efficacy and safety of FOLFOX8 versus mFOLFOX6 combined with bevacizumab or cetuximab as…
- Trial name
- NCT07621497
- Testing
- Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection
- Where
- 3 sites in China
- Volunteers
- 229 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer, Cancer of the Rectum
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
This phase II trial will investigate the combination of adjuvant 5-fluorouracil, radiation, and bevacizumab in patients with stage II and III rectal cancer, followed by FOLFOX6 and bevacizumab.
- Conditions
- Rectal Cancer, Cancer of the Rectum, Colorectal Cancer
- Trial name
- NCT00308516
- Testing
- 5-Fluorouracil, Bevacizumab, Radiation Therapy
- Where
- 14 sites in United States
- Volunteers
- 66 people
- Sponsor
- SCRI Development Innovations, LLC
Rectal Cancer, Chemotherapy Effect
Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Preoperative radiation with single agent chemotherapy as sensitizer is the standard care of locally advanced rectal cancer. Local irradiation significantly increases surgical complications and impairs quality of life.
- Trial name
- NCT03975049
- Testing
- Chemoradiation, FOLFOXIRI Protocol, Folfox Protocol
- Volunteers
- 933 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University